Ruth Adams
Chief Tech/Sci/R&D Officer chez NUVALENT, INC.
Profil
Ruth Adams is currently working as the Vice President-Clinical Operations at Nuvalent, Inc. Prior to this, she worked as the Head-Clinical Operation at Vigeo Therapeutics, Inc. Ms. Adams completed her undergraduate degree from The University of Southampton.
Postes actifs de Ruth Adams
| Sociétés | Poste | Début |
|---|---|---|
| NUVALENT, INC. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
Anciens postes connus de Ruth Adams
| Sociétés | Poste | Fin |
|---|---|---|
Vigeo Therapeutics, Inc.
 Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Formation de Ruth Adams
| The University of Southampton | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NUVALENT, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA. | Health Technology |
